Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | NSD2 | O96028 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 3/20 | 0.33 |
| ▸ | MAOA | P21397 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1893665 | 0.83 | HPGD (0.41) | HPGDALDH1A1MAPK1CYP3A4MAPT | |
| SCHEMBL2092525 | 0.82 | ALDH1A1 (0.35) | HPGDALDH1A1MAPK1CYP3A4MAPT | |
| SCHEMBL3181993 | 0.80 | ALDH1A1 (0.48) | HPGDALDH1A1CYP3A4MAPTKDM4E | |
| SCHEMBL1450340 | 0.80 | SMN1; SMN2 (0.37) | HPGDALDH1A1MAPK1CYP3A4MAPT | |
| SCHEMBL4116744 | 0.78 | KDM4E (0.50) | HPGDALDH1A1MAPK1CYP3A4MAPT | |
| SCHEMBL6756821 | 0.78 | HSP90AB1 (0.47) | HPGDALDH1A1CYP3A4MAPTKDM4E | |
| SCHEMBL1978589 | 0.78 | LMNA (0.55) | ALDH1A1KDM4EPOLBSMN1; SMN2GAA | |
| SCHEMBL443893 | 0.77 | CES2 (0.35) | HPGDALDH1A1MAPK1CYP3A4KMT2A | |
| SCHEMBL7246452 | 0.77 | SMN1; SMN2 (0.36) | HPGDALDH1A1MAPK1CYP3A4MEN1 | |
| SCHEMBL27339754 | 0.77 | ALDH1A1 (0.32) | HPGDALDH1A1MAPK1CYP3A4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6855711-B1 | Pharmaceutical compositions comprising iron chelators for the treatment of neurodegenerative disorders and some novel iron chelators | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2005-02-15 | — | — | US | claimed |
| US-20030176643-A1 | Ethylamine derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-09-18 | — | — | US | claimed |
| US-6586630-B1 | Carbocyclic carboxy amines, used as motilin receptor antagonists for therapy of gastrointerstinal disorders such as irritable bowel syndrome; hormone inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-07-01 | — | — | US | claimed |
| EP-1189606-A2 | NOVEL IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING IRON CHELATORS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | YEDA RESEARCH AND DEVELOPMENT Co. LTD. (IL) | 2002-03-27 | — | — | EP | claimed |
| EP-1116726-A1 | ETHYLAMINE DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-07-18 | — | — | EP | claimed |
| WO-2000074664-A2 | NOVEL IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING IRON CHELATORS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2000-12-14 | — | — | WO | claimed |
| EP-0485984-B1 | Diarylmethoxypiperidine derivatives | UBE INDUSTRIES (JP) | 1996-04-24 | — | — | EP | claimed |
| EP-0485984-A2 | Diarylmethoxypiperidine derivatives | UBE INDUSTRIES, LTD. (JP) | 1992-05-20 | — | — | EP | claimed |
| US-20240159706-A1 | MALDI-MS METHOD, PHOTO-SENSITIVE MALDI MATRIX COMPOSITE AND PHOTO-CAGED MALDI MATRIX COMPOUND FOR USE IN SAID METHOD AND RESPECTIVE USES | SIRIUS FINE CHEMICALS SICHEM GMBH (DE) | 2024-05-16 | — | — | US | disclosed |
| EP-4292121-A1 | MALDI-MS METHOD, PHOTO-SENSITIVE MALDI MATRIX COMPOSITE AND PHOTO-CAGED MALDI MATRIX COMPOUND FOR USE IN SAID METHOD AND RESPECTIVE USES | Sirius Fine Chemicals SiChem GmbH (DE) | 2023-12-20 | — | — | EP | disclosed |
| CN-1206219-C | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL MYERS SQUIBB CO (US) | 2005-06-15 | — | — | CN | disclosed |
| US-6855711-B1 | Pharmaceutical compositions comprising iron chelators for the treatment of neurodegenerative disorders and some novel iron chelators | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2005-02-15 | — | — | US | disclosed |
| US-6720433-B2 | MOTILIN RECEPTOR ANTAGONIST; PHE-N-ME-VAL-(3-(3-METHYLINDOL-5-YL))ALA-NH2;PHE-N-ME-VAL-PHE( 3-ACETYL-4-HYDROXY)-NH2;PHE-N-ME-VAL-(3-(5-TERT-BUTYL-4-SULFAM OYL-2-FURYL))ALA-NH2 | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-04-13 | — | — | US | disclosed |
| US-20030176643-A1 | Ethylamine derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-09-18 | — | — | US | disclosed |
| EP-1189606-A2 | NOVEL IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING IRON CHELATORS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | YEDA RESEARCH AND DEVELOPMENT Co. LTD. (IL) | 2002-03-27 | — | — | EP | disclosed |
| EP-1116726-A1 | ETHYLAMINE DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-07-18 | — | — | EP | disclosed |
| WO-2000074664-A2 | NOVEL IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING IRON CHELATORS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2000-12-14 | — | — | WO | disclosed |
| EP-0485984-B1 | Diarylmethoxypiperidine derivatives | UBE INDUSTRIES (JP) | 1996-04-24 | — | — | EP | disclosed |
| US-5225559-A | DIARYLMETHOXYPIPERIDINE DERIVATIVES | UBE INDUSTRIES, LTD. (JP) | 1993-07-06 | — | — | US | disclosed |
| EP-0485984-A2 | Diarylmethoxypiperidine derivatives | UBE INDUSTRIES, LTD. (JP) | 1992-05-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176643-A1 | Ethylamine derivatives | MLNR, GIPR, MC4R | HPGD 4050/4885ALDH1A1 3007/4885MAPK1 613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.